Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Follicular occlusion tetrad in a male patient with pachyonychia congenita: clinical and genetic analysis.

Musumeci ML, Fiorentini F, Bianchi L, Cascella R, Giardina E, Caputo V, Micali G.

J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:36-39. doi: 10.1111/jdv.15851.

PMID:
31535756
2.

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.

J Med Chem. 2019 Sep 12;62(17):8364. doi: 10.1021/acs.jmedchem.9b01259. Epub 2019 Aug 19. No abstract available.

PMID:
31424209
3.

Beyond active site residues: overall structural dynamics control catalysis in flavin-containing and heme-containing monooxygenases.

Fürst MJ, Fiorentini F, Fraaije MW.

Curr Opin Struct Biol. 2019 Dec;59:29-37. doi: 10.1016/j.sbi.2019.01.019. Epub 2019 Mar 2. Review.

4.

Characterization of a thermostable flavin-containing monooxygenase from Nitrincola lacisaponensis (NiFMO).

Lončar N, Fiorentini F, Bailleul G, Savino S, Romero E, Mattevi A, Fraaije MW.

Appl Microbiol Biotechnol. 2019 Feb;103(4):1755-1764. doi: 10.1007/s00253-018-09579-w. Epub 2019 Jan 4.

PMID:
30607493
5.

The Extreme Structural Plasticity in the CYP153 Subfamily of P450s Directs Development of Designer Hydroxylases.

Fiorentini F, Hatzl AM, Schmidt S, Savino S, Glieder A, Mattevi A.

Biochemistry. 2018 Dec 4;57(48):6701-6714. doi: 10.1021/acs.biochem.8b01052. Epub 2018 Nov 16.

PMID:
30398864
6.

The first ever reported case of malignant fibrous histiocytoma of the scalp.

Marongiu F, Giurdanella A, Fiorentini F, Rubino C.

Int Wound J. 2019 Feb;16(1):302-304. doi: 10.1111/iwj.12982. Epub 2018 Aug 30. No abstract available.

PMID:
30168269
7.

[Extremely elevated erythrosedimentation in an adult population in the City of Buenos Aires].

Otero-Castro V, Bonella B, Cristaldo N, Fiorentini F, Giunta D, Massimino B, Sarapura V, Muñoz AM, Perusini A, Quirós L, Wainsztein V, Warley F, Binder F, Waisman GD, Ferreyro BL.

Rev Chilena Infectol. 2017 Aug;34(4):314-318. doi: 10.4067/s0716-10182017000400314. Spanish.

8.

Baeyer-Villiger Monooxygenase FMO5 as Entry Point in Drug Metabolism.

Fiorentini F, Romero E, Fraaije MW, Faber K, Hall M, Mattevi A.

ACS Chem Biol. 2017 Sep 15;12(9):2379-2387. doi: 10.1021/acschembio.7b00470. Epub 2017 Aug 21.

PMID:
28783300
9.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK.

Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20.

PMID:
28726132
10.

Double-ended Pseudocomedones in Hidradenitis Suppurativa: Clinical, Dermoscopic, and Histopatho-logical Correlation.

Lacarrubba F, Musumeci ML, Nasca MR, Verzì AE, Fiorentini F, Micali G.

Acta Derm Venereol. 2017 Jun 9;97(6):763-764. doi: 10.2340/00015555-2601. No abstract available.

11.

Institutional Registry of Elderly Patients With Hip Fracture in a Community-Based Tertiary Care Hospital in Argentina (RIAFC).

Benchimol J, Fiorentini F, Elizondo CM, Boietti BR, Carabelli G, Barla J, Sancineto C, Waisman GD, Giunta DH.

Geriatr Orthop Surg Rehabil. 2016 Sep;7(3):121-5. doi: 10.1177/2151458516651309. Epub 2016 Jun 15.

12.

Psychopathological Variables and Sleep Quality in Psoriatic Patients.

Luca M, Luca A, Musumeci ML, Fiorentini F, Micali G, Calandra C.

Int J Mol Sci. 2016 Jul 21;17(7). pii: E1184. doi: 10.3390/ijms17071184.

13.

Long Chain Alcohols Produced by Trichoderma citrinoviride Have Phagodeterrent Activity against the Bird Cherry-Oat Aphid Rhopalosiphum padi.

Ganassi S, Grazioso P, De Cristofaro A, Fiorentini F, Sabatini MA, Evidente A, Altomare C.

Front Microbiol. 2016 Mar 10;7:297. doi: 10.3389/fmicb.2016.00297. eCollection 2016.

14.

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.

J Med Chem. 2016 Apr 14;59(7):3392-408. doi: 10.1021/acs.jmedchem.6b00064. Epub 2016 Mar 30. Erratum in: J Med Chem. 2019 Sep 12;62(17):8364.

PMID:
27003761
15.

A Rare Case of Mondor Syndrome after Breast Reduction Surgery. Insert it into the Consent Form.

Marongiu F, Bulla A, Fiorentini F, Campus G, Rubino C.

Breast J. 2016 Mar-Apr;22(2):249-51. doi: 10.1111/tbj.12560. Epub 2016 Jan 22. No abstract available.

PMID:
26799168
16.

Biocatalytic Characterization of Human FMO5: Unearthing Baeyer-Villiger Reactions in Humans.

Fiorentini F, Geier M, Binda C, Winkler M, Faber K, Hall M, Mattevi A.

ACS Chem Biol. 2016 Apr 15;11(4):1039-48. doi: 10.1021/acschembio.5b01016. Epub 2016 Feb 1.

PMID:
26771671
17.

PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation.

Adage T, Del Bene F, Fiorentini F, Doornbos RP, Zankl C, Bartley MR, Kungl AJ.

Cytokine. 2015 Dec;76(2):433-441. doi: 10.1016/j.cyto.2015.08.006. Epub 2015 Aug 21.

PMID:
26303011
18.

[Pneumocystis jiroveci infection in patients with and without HIV: A comparison].

Rey A, Losada C, Santillán J, Fiorentini F, Schiaffino M, Peroni HJ, Giunta D, Barcán L, Waisman G.

Rev Chilena Infectol. 2015 Apr;32(2):175-80. doi: 10.4067/S0716-10182015000300006. Spanish.

19.

Relationship between repeated sprint ability and aerobic capacity in professional soccer players.

Jones RM, Cook CC, Kilduff LP, Milanović Z, James N, Sporiš G, Fiorentini B, Fiorentini F, Turner A, Vučković G.

ScientificWorldJournal. 2013 Oct 1;2013:952350. doi: 10.1155/2013/952350. eCollection 2013.

20.

CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.

Ross J, Sharma S, Winston J, Nunez M, Bottini G, Franceschi M, Scarpini E, Frigerio E, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calza L, Norris D, Cicirello H, Casula D, Imbimbo BP.

Curr Alzheimer Res. 2013 Sep;10(7):742-53.

PMID:
23968157
21.

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study.

Ross J, Sharma S, Winston J, Nunez M, Bottini G, Franceschi M, Scarpini E, Frigerio E, Fiorentini F, Fernandez M, Sivilia S, Giardin L, Calzà L, Norris D, Cicirello H, Casula D, Imbimbo B.

Curr Alzheimer Res. 2013 Aug 2. [Epub ahead of print]

PMID:
23952019
22.

Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.

Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V.

Mol Med. 2013 May 20;19:79-87. doi: 10.2119/molmed.2013.00011.

23.

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, Fiorentini F, Gravina G, Mercurio C, Pastori W, Brasca M, Pesenti E, Galvani A, Ciomei M.

Br J Pharmacol. 2013 May;169(1):156-66. doi: 10.1111/bph.12112.

24.

Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.

Imbimbo BP, Frigerio E, Breda M, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calzà L, Norris D, Casula D, Shenouda M.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):278-86. doi: 10.1097/WAD.0b013e3182622ace.

PMID:
22922591
25.

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J.

Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7.

26.

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD.

Invest New Drugs. 2012 Dec;30(6):2334-43. doi: 10.1007/s10637-011-9774-6. Epub 2011 Dec 9.

27.

5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.

Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):96-101. doi: 10.1016/j.bmcl.2011.11.065. Epub 2011 Nov 23.

PMID:
22154349
28.

Effects of speed, agility, quickness training method on power performance in elite soccer players.

Jovanovic M, Sporis G, Omrcen D, Fiorentini F.

J Strength Cond Res. 2011 May;25(5):1285-92. doi: 10.1519/JSC.0b013e3181d67c65.

PMID:
21522073
29.

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.

Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.

Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. doi: 10.1016/j.bmcl.2011.03.054. Epub 2011 Mar 21.

PMID:
21470862
30.

4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.

Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6489-94. doi: 10.1016/j.bmcl.2010.09.060. Epub 2010 Sep 17.

PMID:
20932759
31.

Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.

Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.

J Med Chem. 2010 Oct 28;53(20):7296-315. doi: 10.1021/jm100504d.

PMID:
20873740
32.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.

Mol Cancer Ther. 2010 Aug;9(8):2243-54. doi: 10.1158/1535-7163.MCT-10-0190. Epub 2010 Aug 3.

33.

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.

Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, Airoldi M, Schena M, MacArthur R, Weitman S, Jannuzzo MG, Crippa S, Fiorentini F, Petroccione A, Comis S.

Cancer Chemother Pharmacol. 2010 Jul;66(2):389-94. doi: 10.1007/s00280-009-1175-6. Epub 2009 Nov 22.

PMID:
20480279
34.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Locatelli G, Bosotti R, Ciomei M, Brasca MG, Calogero R, Mercurio C, Fiorentini F, Bertolotti M, Scacheri E, Scaburri A, Galvani A, Pesenti E, De Baere T, Soria JC, Lazar V, Isacchi A.

Mol Cancer Ther. 2010 May;9(5):1265-73. doi: 10.1158/1535-7163.MCT-09-1163. Epub 2010 Apr 27.

35.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.

Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. doi: 10.1016/j.bmc.2010.01.042. Epub 2010 Jan 25.

PMID:
20153204
36.

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG.

J Med Chem. 2010 Mar 11;53(5):2171-87. doi: 10.1021/jm901710h.

PMID:
20141146
37.

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.

Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, Magni P, De Nicolao G.

Eur J Cancer. 2009 Dec;45(18):3336-46. doi: 10.1016/j.ejca.2009.09.025. Epub 2009 Oct 23.

PMID:
19854637
38.

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.

J Med Chem. 2009 Aug 27;52(16):5152-63. doi: 10.1021/jm9006559.

PMID:
19603809
39.

Predictive value of assessment of disc-radicular conflict of the cervical segment by somatosensory evoked potentials.

Titlic M, Kolic K, Fiorentini F, Josipovic-Jelic Z.

Bratisl Lek Listy. 2009;110(5):312-5.

PMID:
19507670
40.

First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.

Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E.

J Med Chem. 2009 Jan 22;52(2):293-307. doi: 10.1021/jm800977q. Erratum in: J Med Chem. 2009 Feb 26;52(4):1230.

PMID:
19115845
41.

Effects of acid rain on soil humic compounds.

Calace N, Fiorentini F, Petronio BM, Pietroletti M.

Talanta. 2001 Jun 21;54(5):837-46.

PMID:
18968306
42.

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.

Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C.

Nat Chem Biol. 2008 Jun;4(6):357-65. doi: 10.1038/nchembio.90. Epub 2008 May 11.

PMID:
18469809
43.

6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors.

Brasca MG, Albanese C, Amici R, Ballinari D, Corti L, Croci V, Fancelli D, Fiorentini F, Nesi M, Orsini P, Orzi F, Pastori W, Perrone E, Pesenti E, Pevarello P, Riccardi-Sirtori F, Roletto F, Roussel P, Varasi M, Vulpetti A, Mercurio C.

ChemMedChem. 2007 Jun;2(6):841-52.

PMID:
17450625
44.

Retroviral microarray-based platform on nanostructured TiO2 for functional genomics and drug discovery.

Carbone R, Giorgetti L, Zanardi A, Marangi I, Chierici E, Bongiorno G, Fiorentini F, Faretta M, Piseri P, Pelicci PG, Milani P.

Biomaterials. 2007 Apr;28(13):2244-53. Epub 2007 Jan 5.

PMID:
17276506
45.

Adhesion and proliferation of fibroblasts on cluster-assembled nanostructured carbon films: the role of surface morphology.

Lenardi C, Perego C, Cassina V, Podestà A, D'Amico A, Gualandris D, Vinati S, Fiorentini F, Bongiorno G, Piserj P, Vellea Sacchi F, Milani P.

J Nanosci Nanotechnol. 2006 Dec;6(12):3718-30.

PMID:
17256321
46.

A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.

Nesi M, Borghi D, Brasca MG, Fiorentini F, Pevarello P.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3205-8. Epub 2006 Apr 17.

PMID:
16616492
47.

Biocompatibility of cluster-assembled nanostructured TiO2 with primary and cancer cells.

Carbone R, Marangi I, Zanardi A, Giorgetti L, Chierici E, Berlanda G, Podestà A, Fiorentini F, Bongiorno G, Piseri P, Pelicci PG, Milani P.

Biomaterials. 2006 Jun;27(17):3221-9. Epub 2006 Feb 28.

PMID:
16504283
48.

[BCG vaccination against tuberculosis in the health system].

Bugiani M, Besozzi G, Codecasa L, Migliori GB, Fiorentini F; Gruppo di studio AIPO Tubercolosi.

Med Lav. 2005 Mar-Apr;96(2):178-80. Italian. No abstract available.

PMID:
16001519
49.

Management of multidrug-resistant tuberculosis in Italy.

Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB.

Int J Tuberc Lung Dis. 2005 May;9(5):507-13.

PMID:
15875921
50.

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.

Pevarello P, Brasca MG, Orsini P, Traquandi G, Longo A, Nesi M, Orzi F, Piutti C, Sansonna P, Varasi M, Cameron A, Vulpetti A, Roletto F, Alzani R, Ciomei M, Albanese C, Pastori W, Marsiglio A, Pesenti E, Fiorentini F, Bischoff JR, Mercurio C.

J Med Chem. 2005 Apr 21;48(8):2944-56. Erratum in: J Med Chem. 2005 Jul 28;48(15):5058.

PMID:
15828833

Supplemental Content

Loading ...
Support Center